This Article Full Text (PDF) Corrected Article References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McGough, J. J. Articles by Moon, E. Search for Related Content PubMed PubMed Citation Articles by McGough, J. J. Articles by Moon, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Attention Deficit Hyperactivity Disorder Hazardous Substances DB METHYLPHENIDATE Social Bookmarking                         What's this?

A Randomized, Double-Blind, Placebo-Controlled, Laboratory Classroom Assessment of Methylphenidate Transdermal System in Children With ADHD

University of California, Los Angeles, Semel Institute for Neuroscience and Human Behavior, jmcgough{at}mednet.ucla.edu

Sharon B. Wigal

University of California, Irvine, Child Development Center

Howard Abikoff

New York University Child Study Center

John M. Turnbow

Texas Tech University Medical School

Kelly Posner

New York State Psychiatric Institute

Eliot Moon

Elite Clinical Trials, Temecula, California

Objective: This study evaluates the efficacy, duration of action, and tolerability of methylphenidate transdermal system (MTS) in children with ADHD. Method: Participants were dose optimized over 5 weeks utilizing patch doses of 10, 16, 20, and 27 mg applied in the morning and worn for 9 hours. Following optimization, 80 participants were randomized to 1 week of MTS or placebo followed by 1 week of the opposite treatment. Laboratory classroom sessions conducted after each randomized week included blinded ratings of attention, behavior, and academic performance. Results: MTS was well tolerated and displayed significant improvement compared with placebo. Improvements were seen at the first postdose time point measured and continued through 12 hours. Conclusions: Treatment with MTS resulted in statistically significant improvements on all efficacy measures. Time course and therapeutic effects of MTS suggest that this novel methylphenidate delivery system is an efficacious once-daily treatment for ADHD.

Key Words: methylphenidate transdermal system • ADHD • laboratory classroom study • stimulant • patch

Journal of Attention Disorders, Vol. 9, No. 3, 476-485 (2006)
DOI: 10.1177/1087054705284089


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Chavez, M. A Sopko Jr., M. J Ehret, R. E Paulino, K. R Goldberg, K. Angstadt, and G. T Bogart An Update on Central Nervous System Stimulant Formulations in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Ann. Pharmacother., June 1, 2009; 43(6): 1084 - 1095. [Abstract] [Full Text] [PDF]

				R. M. Scheffler, T. T. Brown, B. D. Fulton, S. P. Hinshaw, P. Levine, and S. Stone Positive Association Between Attention-Deficit/ Hyperactivity Disorder Medication Use and Academic Achievement During Elementary School Pediatrics, May 1, 2009; 123(5): 1273 - 1279. [Abstract] [Full Text] [PDF]

				E. J. Dommett, E. L. Henderson, M. S. Westwell, and S. A. Greenfield Methylphenidate amplifies long-term plasticity in the hippocampus via noradrenergic mechanisms Learn. Mem., August 6, 2008; 15(8): 580 - 586. [Abstract] [Full Text] [PDF]

				Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder Focus, July 1, 2008; 6(3): 401 - 426. [Abstract] [Full Text] [PDF]